Daren Tang (600329.SH) announced its 2023 annual results, with net profit of 987 million yuan, an increase of 14.49% over the previous year. It plans to distribute 10 to 12.8 yuan

According to the Zhitong Finance App, Daren Tang (600329.SH) disclosed the 2023 annual report. The company achieved revenue of 8.222 billion yuan in 2023, a year-on-year decrease of 0.33%; net profit to mother of 987 million yuan, an increase of 14.49%; deducted non-net profit of 952 million yuan, an increase of 23.8%; and basic earnings per share of 1.28 yuan. The company plans to distribute a cash dividend of 12.8 yuan (tax included) for every 10 shares to all shareholders. In 2023, the company will firmly implement “focus on the market, effective innovation, organizational governance, co-creation and sharing, drive both industry and finance, control capital and loss, digital empowerment, and cultural goods

Zhitong FinanceMar 29 06:36 ET

Singapore-listed Manufacturers Book Mixed Returns in Early 2024

Singapore's manufacturing sector moderated in 2023, with a 4.3% contraction, reversing the 2.7% growth in 2022. Looking forward, the Ministry of Trade and Industry (MTI) expect that as global electronics demand recovers, Singapore's manufacturing and trade-related sectors will see a gradual improvement in growth.

Singapore ExchangeFeb 19 04:21 ET

Portion of Tianjin Pharmaceutical Controlling Shareholder's Shares Placed Under Judicial Freeze

A portion of Tianjin Pharmaceutical (SGX:T14) controlling shareholder Tianjin Pharmaceutical Holdings' shares have been placed under judicial freeze, according to a Tuesday bourse filing. The shares,

MT NewswiresJan 9 18:23 ET

Tianjin Pharmaceutical Taps Affiliate for Brand Promotion

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) will engage Tianjin Pharmaceutical Group Marketing for brand promotion and marketing business expansion. Under the agreement, Tianjin Pharmaceutical

MT NewswiresDec 20, 2023 03:24 ET

Tianjin Pharmaceutical Hires Contractor for Renovation of Workshop, Warehouses

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) entered into a construction contract with Tianjin Pharmaceutical Design Institute for the decoration of a workshop and renovation of warehouses. Unde

MT NewswiresDec 19, 2023 23:38 ET

Da Ren Tang (600329.SH): Intends to sign a contract with Tianjin Pharmaceutical Design Institute Co., Ltd.

Gelonghui (600329.SH) announced on December 19丨Da Rentang () announced that in order to integrate the medicinal herbs and tablet business lines and achieve integrated management of tablets and related businesses, the company plans to build a new tablet production workshop, decoction center and supporting facilities in the existing Qingguang South Reservoir area, and upgrade warehouses in the northern storage area. Based on this plan, the company plans to carry out the “Jinyao Da Rentang Drink Factory Relocation and Renovation Project - Frying Workshop Single Project” and the “Jinyao Da Rentang Pharmaceutical Company Qingguang Reservoir North Reservoir Area Renovation Project - 27 #29 #43 #库改造工程” project. According to the bidding results, Tianjin Pharmaceutical Design Institute Co., Ltd.

Gelonghui FinanceDec 19, 2023 04:16 ET